Eiger BioPharmaceuticals Enters into $75M Term Loan Agreement and $5M Stock Purchase Agreement with Innovatus Capital Partners to Refinance Existing Debt Facility and Further Strengthen Cash Position Ahead of Key Milestones

Eiger nets approximately $11M after retiring its existing debt facility Immediately bolsters cash position and provides access to an additional $35M in non-dilutive capital on clinical and regulatory milestones PALO ALTO, Calif., June 7, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc....

Click to view original post